Methods and endpoint issues in clinical development of lipid-acting agents with pleiotropic effects.
Davignon
J
J
Hyperlipidemia and Atherosclerosis Research Group, Clinical Research Institute of Montreal, QC, Canada.
D000818:Animals; D002994:Clofibrate / Q000494:pharmacology*; D004341:Drug Evaluation / Q000379:methods*; D004353:Drug Evaluation, Preclinical; D015507:Drugs, Investigational / Q000494:pharmacology; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology*; D006949:Hyperlipidemias / Q000188:drug therapy; D000960:Hypolipidemic Agents / Q000494:pharmacology*; D007880:Legislation, Drug; D011341:Probucol / Q000494:pharmacology*
D015507:Drugs, Investigational; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D002994:Clofibrate; D011341:Probucol